Guo-Chun Zhou - Publications

Affiliations: 
Nanjing University of Technology 

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Zhou GF, Li F, Xue JX, Qian W, Gu XR, Zheng CB, Li C, Yang LM, Xiong SD, Zhou GC, Zheng YT. Antiviral effects of the fused tricyclic derivatives of indoline and imidazolidinone on ZIKV infection and RdRp activities of ZIKV and DENV. Virus Research. 199062. PMID 36746341 DOI: 10.1016/j.virusres.2023.199062  0.342
2023 Chen R, Francese R, Wang N, Li F, Sun X, Xu B, Liu J, Liu Z, Donalisio M, Lembo D, Zhou GC. Exploration of novel hexahydropyrrolo[1,2-e]imidazol-1-one derivatives as antiviral agents against ZIKV and USUV. European Journal of Medicinal Chemistry. 248: 115081. PMID 36623328 DOI: 10.1016/j.ejmech.2022.115081  0.36
2022 Qian W, Zhou GF, Ge X, Xue JX, Zheng CB, Yang LM, Gu XR, Li C, Xiong SD, Zheng YT, Zhou GC. Discovery of dehydroandrographolide derivatives with C19 hindered ether as potent anti-ZIKV agents with inhibitory activities to MTase of ZIKV NS5. European Journal of Medicinal Chemistry. 243: 114710. PMID 36055002 DOI: 10.1016/j.ejmech.2022.114710  0.318
2022 Qian W, Xue JX, Xu J, Li F, Zhou GF, Wang F, Luo RH, Liu J, Zheng YT, Zhou GC. Design, synthesis, discovery and SAR of the fused tricyclic derivatives of indoline and imidazolidinone against DENV replication and infection. Bioorganic Chemistry. 120: 105639. PMID 35093691 DOI: 10.1016/j.bioorg.2022.105639  0.39
2020 Xu B, Lee EM, Medina A, Sun X, Wang D, Tang H, Zhou GC. Inhibition of zika virus infection by fused tricyclic derivatives of 1,2,4,5-tetrahydroimidazo[1,5-a]quinolin-3(3aH)-one. Bioorganic Chemistry. 104: 104205. PMID 32916389 DOI: 10.1016/J.Bioorg.2020.104205  0.303
2019 Li F, Lee EM, Sun X, Wang D, Tang H, Zhou GC. Design, synthesis and discovery of andrographolide derivatives against Zika virus infection. European Journal of Medicinal Chemistry. 187: 111925. PMID 31838328 DOI: 10.1016/J.Ejmech.2019.111925  0.343
2016 Weng Z, Shao X, Graf D, Wang C, Klein CD, Wang J, Zhou GC. Identification of fused bicyclic derivatives of pyrrolidine and imidazolidinone as dengue virus-2 NS2B-NS3 protease inhibitors. European Journal of Medicinal Chemistry. 125: 751-759. PMID 27721158 DOI: 10.1016/J.Ejmech.2016.09.063  0.341
2013 Zhou GC, Weng Z, Shao X, Liu F, Nie X, Liu J, Wang D, Wang C, Guo K. Discovery and SAR studies of methionine-proline anilides as dengue virus NS2B-NS3 protease inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 6549-54. PMID 24268549 DOI: 10.1016/J.Bmcl.2013.10.071  0.358
2013 Zhou GC, Liu F, Wan J, Wang J, Wang D, Wei P, Ouyang P. Design, synthesis and evaluation of a cellular stable and detectable biotinylated fumagillin probe and investigation of cell permeability of fumagillin and its analogs to endothelial and cancer cells. European Journal of Medicinal Chemistry. 70: 631-9. PMID 24211639 DOI: 10.1016/J.Ejmech.2013.10.033  0.302
2010 Cheng H, Zhang L, Liu Y, Chen S, Cheng H, Lu X, Zheng Z, Zhou GC. Design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines. European Journal of Medicinal Chemistry. 45: 5950-7. PMID 20974505 DOI: 10.1016/j.ejmech.2010.09.061  0.351
2010 Liu X, Ou Y, Chen S, Lu X, Cheng H, Jia X, Wang D, Zhou GC. Synthesis and inhibitory evaluation of cyclohexen-2-yl- and cyclohexyl-substituted phenols and quinones to endothelial cell and cancer cells. European Journal of Medicinal Chemistry. 45: 2147-53. PMID 20149494 DOI: 10.1016/j.ejmech.2010.01.051  0.315
2009 Chen Y, Chen S, Lu X, Cheng H, Ou Y, Cheng H, Zhou GC. Synthesis, discovery and preliminary SAR study of benzofuran derivatives as angiogenesis inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 1851-4. PMID 19272775 DOI: 10.1016/j.bmcl.2009.02.082  0.371
Show low-probability matches.